Histology of good risk non-seminomatous germ cell tumour (NSGCT) patients following retroperitoneal lymph node dissection (PC-RPLND) after four cycles of etoposide and cisplatin (Epx4)

被引:0
|
作者
Patel, MI [1 ]
Beck, SDW [1 ]
Sheinfeld, J [1 ]
机构
[1] Univ Sydney, Sydney, NSW 2006, Australia
关键词
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:3 / 3
页数:1
相关论文
共 50 条
  • [31] RATES OF TERATOMA AT POST-CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION BY INDUCTION CHEMOTHERAPY REGIMEN FOR GOOD RISK NON-SEMINOMATOUS GERM CELL TUMORS
    Kundu, Shilajit
    Carver, Brett
    Bajorin, Dean
    Motzer, Robert
    Bosl, George
    Feldman, Darren
    Sheinfeld, Joel
    JOURNAL OF UROLOGY, 2011, 185 (04): : E334 - E334
  • [32] Study of the conformity of post-chemotherapy retroperitoneal lymph-node dissection (RPLND) to standard recommendations in patients with testicular (T) and primary retroperitoneal (PR) non-seminomatous germ-cell tumor (NSGCT): Impact on outcome.
    Flechon, A
    Tavernier, E
    Meeus, P
    Rivoire, M
    Droz, JP
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 402S - 402S
  • [33] Prognostic clinical parameters to predict the necessity of reconstructive vascular surgery for patients who undergo postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) for advanced nonseminatous germ cell tumors (NSGCT)
    Heidenreich, A.
    Schrader, M.
    Dieckmann, K.
    Winter, C.
    Pfister, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [34] Long term results from retroperitoneal lymph node dissection (RPLND) for post chemotherapy non-seminomatous germ cell tumours at a high volume single centre
    Patel, P.
    Mak, D.
    Evison, F.
    Gourevitch, D.
    Wallace, M.
    BJU INTERNATIONAL, 2014, 113 : 40 - 40
  • [36] Outcomes after primary retroperitoneal lymph node dissection in men with stage 2 non-seminomatous germ cell tumour: A multicenter retrospective cohort study.
    Antonelli, Luca
    Heidenreich, Axel
    Bagrodia, Aditya
    Branger, Nicolas
    Clinton, Timothy
    Daneshmand, Siamak
    Djaladat, Hooman
    Hamilton, Robert James
    Ho, Matthew
    Sexton, Wade J.
    Nicol, David
    Nicolai, Nicola
    Olson, Kathleen
    Porter, James
    Singla, Nirmish
    Stroup, Sean P.
    Terbuch, Angelika
    Cary, Clint
    Fankhauser, Christian Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 516 - 516
  • [37] PROGNOSTIC CLINICAL PARAMETERS TO PREDICT THE NECESSITY OF RECONSTRUCTIVE VASCULAR SURGERY FOR PATIENTS WHO UNDERGO POST-CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION (PC-RPLND) FOR ADVANCED NONSEMINATOUS GERM CELL TUMORS (NSGCT)
    Heidenreich, A.
    Dieckmann, K. P.
    Busch, F.
    Schrader, M.
    Schmelz, H.
    Krege, S.
    Winter, C.
    Pfister, D.
    EUROPEAN UROLOGY SUPPLEMENTS, 2011, 10 (02) : 321 - 321
  • [38] Post-chemotherapy retroperitoneal lymph node dissection can not be safely omitted in patients with metastatic non-seminomatous germ cell testis cancer
    Nguyen, Carvell T.
    Subramanian, Vairavan S.
    Stephenson, Andrew J.
    Klein, Eric A.
    JOURNAL OF UROLOGY, 2008, 179 (04): : 176 - 176
  • [39] OPEN (O) AND LAPAROSCOPIC (L) RETROPERITONEAL LYMPH-NODE DISSECTION (RPLND) FOR CLINICAL STAGE I NON SEMINOMATOUS GERM-CELL TESTIS TUMOURS (NSGCT): EXPERIENCE OF A SINGLE CENTER
    Nicolai, N.
    Biasoni, D.
    Autran Gomez, A. M.
    Catanzaro, M.
    Milani, A.
    Necchi, A.
    Piva, L.
    Stagni, S.
    Torelli, T.
    Salvioni, R.
    EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (02) : 236 - 236